Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the combination of cisplatin (or carboplatin) and gemcitabine, along with immunotherapy such as nivolumab. After the initial treatment is finished, patients may continue to receive additional immunotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Giving BMS-986016 in addition to the usual immunotherapy after initial treatment may extend the time without the tumor cells growing or spreading longer than the usual approach in patients with recurrent or metastatic nasopharyngeal cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak nosogardła, który powrócił lub rozprzestrzenił się w ciele.
- •Choroba nie kwalifikuje się do leczenia operacyjnego lub ponownego napromieniowania, jeśli chodzi o nawrót miejscowy.
- •Potwierdzone jest, że komórki guza produkują lub są związane z wirusem Epsteina-Barr (EBV).
- •Widoczne ogniska choroby na badaniach obrazowych, które można zmierzyć.
- •Pacjenci z przerzutami do mózgu lub opon mózgowych, którzy są w stabilnym stanie po wcześniejszym leczeniu tych zmian i odstawili silne sterydy.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (88)
Kaiser Permanente Dublin
Dublin, United States
Kaiser Permanente-Fremont
Fremont, United States
Kaiser Permanente Fresno Orchard Plaza
Fresno, United States
Kaiser Permanente-Fresno
Fresno, United States
Keck Medicine of USC Koreatown
Los Angeles, United States
Los Angeles General Medical Center
Los Angeles, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, United States
Kaiser Permanente- Modesto MOB II
Modesto, United States
Kaiser Permanente-Modesto
Modesto, United States
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, United States
Kaiser Permanente-Oakland
Oakland, United States
Stanford Cancer Institute Palo Alto
Palo Alto, United States
Kaiser Permanente-Roseville
Roseville, United States
Kaiser Permanente Downtown Commons
Sacramento, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
Kaiser Permanente-South Sacramento
Sacramento, United States
Kaiser Permanente-San Francisco
San Francisco, United States
Kaiser Permanente-Santa Teresa-San Jose
San Jose, United States
Kaiser Permanente San Leandro
San Leandro, United States
Kaiser San Rafael-Gallinas
San Rafael, United States
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, United States
Kaiser Permanente-Santa Rosa
Santa Rosa, United States
Kaiser Permanente-South San Francisco
South San Francisco, United States
Kaiser Permanente-Vallejo
Vallejo, United States
Kaiser Permanente-Walnut Creek
Walnut Creek, United States
Emory University Hospital Midtown
Atlanta, United States
Kaiser Permanente Moanalua Medical Center
Honolulu, United States
Saint Alphonsus Cancer Care Center-Boise
Boise, United States
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, United States
Kootenai Health - Coeur d'Alene
Coeur d'Alene, United States
Saint Alphonsus Cancer Care Center-Nampa
Nampa, United States
Kootenai Clinic Cancer Services - Post Falls
Post Falls, United States
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, United States
Northwestern University
Chicago, United States
University of Illinois
Chicago, United States
Carle at The Riverfront
Danville, United States
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, United States
Carle Physician Group-Effingham
Effingham, United States
Northwestern Medicine Cancer Center Delnor
Geneva, United States
Northwestern Medicine Glenview Outpatient Center
Glenview, United States
Northwestern Medicine Grayslake Outpatient Center
Grayslake, United States
Northwestern Medicine Lake Forest Hospital
Lake Forest, United States
Carle Physician Group-Mattoon/Charleston
Mattoon, United States
Northwestern Medicine Orland Park
Orland Park, United States
Carle Cancer Center
Urbana, United States
Northwestern Medicine Cancer Center Warrenville
Warrenville, United States
UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, United States
Saint Anthony Regional Hospital
Carroll, United States
UI Health Care Mission Cancer and Blood - West Des Moines Clinic
Clive, United States
Heartland Oncology and Hematology LLP
Council Bluffs, United States
Methodist Jennie Edmundson Hospital
Council Bluffs, United States
Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ
Council Bluffs, United States
Iowa Methodist Medical Center
Des Moines, United States
UI Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines, United States
Broadlawns Medical Center
Des Moines, United States
Mercy Medical Center - Des Moines
Des Moines, United States
UI Health Care Mission Cancer and Blood - Laurel Clinic
Des Moines, United States
UI Healthcare Mission Cancer and Blood - Fort Dodge
Fort Dodge, United States
UI Health Care Mission Cancer and Blood - Waukee Clinic
Waukee, United States
Mercy Hospital South
St Louis, United States
Mercy Hospital Saint Louis
St Louis, United States
Community Hospital of Anaconda
Anaconda, United States
Billings Clinic Cancer Center
Billings, United States
Bozeman Health Deaconess Hospital
Bozeman, United States
Benefis Sletten Cancer Institute
Great Falls, United States
Logan Health Medical Center
Kalispell, United States
Community Medical Center
Missoula, United States
Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
Omaha, United States
Nebraska Methodist Hospital
Omaha, United States
Oncology Associates PC
Omaha, United States
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, United States
University of Cincinnati Cancer Center-West Chester
West Chester, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa, United States
Saint Alphonsus Cancer Care Center-Ontario
Ontario, United States
Providence Portland Medical Center
Portland, United States
Providence Saint Vincent Medical Center
Portland, United States
Medical University of South Carolina
Charleston, United States
Swedish Medical Center-First Hill
Seattle, United States
ProHealth D N Greenwald Center
Mukwonago, United States
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, United States
ProHealth Waukesha Memorial Hospital
Waukesha, United States
UW Cancer Center at ProHealth Care
Waukesha, United States
Peter MacCallum Cancer Centre
Melbourne, Australia
University Health Network-Princess Margaret Hospital
Toronto, Canada
Chinese University of Hong Kong-Prince of Wales Hospital
Shatin, Hong Kong
National University Hospital Singapore
Singapore, Singapore
National Cancer Centre Singapore
Singapore, Singapore
Trial contact
Site Public Contact
Jed A. Katzel
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Jacob S. Thomas
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Alexander D. Colevas
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Siao-Yi Wang
PRINCIPAL_INVESTIGATOR
Site Public Contact
Conor E. Steuer
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
John M. Schallenkamp
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jochen H. Lorch
PRINCIPAL_INVESTIGATOR
Site Public Contact
Ameen Salahudeen
PRINCIPAL_INVESTIGATOR
Site Public Contact
Prem Sobti
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Seema Harichand-Herdt
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Yungpo B. Su
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Richard L. Deming
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Jay W. Carlson
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Minh Phan
PRINCIPAL_INVESTIGATOR
Site Public Contact
Dan S. Zuckerman
PRINCIPAL_INVESTIGATOR
Site Public Contact
John M. Kaczmar
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Timothy R. Wassenaar
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Enrique Sanz Garcia
PRINCIPAL_INVESTIGATOR
Site Public Contact
Brigette B. Ma
PRINCIPAL_INVESTIGATOR
Site Public Contact
Boon C. Goh
PRINCIPAL_INVESTIGATOR
Site Public Contact
Wan Teck D. Lim
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.